Affordable Access

deepdyve-link
Publisher Website

68Ga-PSMA PET/CT Versus 18F-FDG PET/CT for Imaging of Hepatocellular Carcinoma

Authors
  • Gündoğan, Cihan1
  • Ergül, Nurhan2
  • Çakır, Mehmet Semih3
  • Kılıçkesmez, Özgür3
  • Gürsu, Rıza Umar4
  • Aksoy, Tamer2
  • Çermik, Tevfik Fikret2
  • 1 University of Health Sciences Turkey, Gazi Yaşargil Training and Research Hospital, Clinic of Nuclear Medicine, Diyarbakır, Turkey
  • 2 University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Turkey
  • 3 University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Radiology, İstanbul, Turkey
  • 4 University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of Medical Oncology, İstanbul, Turkey
Type
Published Article
Journal
Molecular Imaging and Radionuclide Therapy
Publisher
Galenos Publishing
Publication Date
Jun 03, 2021
Volume
30
Issue
2
Pages
79–85
Identifiers
DOI: 10.4274/mirt.galenos.2021.92053
PMID: 34082503
PMCID: PMC8185475
Source
PubMed Central
Keywords
Disciplines
  • Original Article
License
Unknown

Abstract

Objectives: This study aimed to compare the metabolic parameters obtained from 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) and gallium-68 (68Ga)-prostate-specific membrane antigen (PSMA) PET/CT and investigate the relationship between serum alpha-fetoprotein and PET scan parameters in patients with hepatocellular carcinoma. Methods: Fourteen patients were recruited after dynamic magnetic resonance imaging (MRI) of the upper abdomen, and 18F-FDG and 68Ga-PSMA PET/CT imaging studies were conducted. Regions of interest (ROIs) were drawn from lesion-free liver tissue, abdominal aorta (A), and right medial gluteal muscle (G) for the background activity. Maximum standard uptake value (SUVmax) of these regions were compared with the SUVmax of primary tumor (T). Results: On visual assessment, five patients (36%) experienced low 18F-FDG uptake in the primary lesion, three patients (21%) experienced moderate uptake, and six patients (43%) experienced high uptake. However, only one patient (7%) showed low 68Ga-PSMA uptake, two patients (14%) showed moderate uptake, and 11 patients (79%) showed high uptake. Four patients with a low 18F-FDG uptake showed high 68Ga-PSMA uptake, while one patient exhibited low uptake with both 18F-FDG and 68Ga-PSMA. The number of lesions on 68Ga-PSMA PET/CT and MRI was significantly higher than 18F-FDG PET/CT (p=0.042 and 0.026, respectively). T/A and T/G values were significantly higher in 68Ga-PSMA than 18F-FDG (p=0.002 and 0.002, respectively). Conclusion: 68Ga-PSMA PET/CT is superior to 18F-FDG PET/CT in the staging of hepatocellular carcinoma. High 68Ga-PSMA uptake could be promising for PSMA-targeted radionuclide treatments.

Report this publication

Statistics

Seen <100 times